Brokers Set Expectations for ELVN FY2027 Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Stock analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Enliven Therapeutics in a research report issued to clients and investors on Monday, October 19th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($2.06) for the year. HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.81) per share.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10).

A number of other equities analysts have also issued reports on ELVN. Guggenheim reissued a “buy” rating on shares of Enliven Therapeutics in a research report on Thursday, October 8th. JPMorgan Chase & Co. assumed coverage on shares of Enliven Therapeutics in a research note on Thursday, October 1st. They set an “overweight” rating and a $75.00 price objective for the company. Stifel Nicolaus upped their price objective on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, August 6th. William Blair started coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Ten analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $75.44.

Enliven Therapeutics Stock Up 3.7%

Shares of NASDAQ ELVN opened at $38.70 on Tuesday. The business’s 50 day moving average price is $51.60 and its 200 day moving average price is $47.95. The firm has a market cap of $2.84 billion, a P/E ratio of -23.17 and a beta of 0.24. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $50.35, for a total value of $303,006.30. Following the completion of the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at $1,913,300. The trade was a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika Derynck sold 158,795 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the transaction, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 183,831 shares of company stock worth $10,823,298. Insiders own 3.00% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ELVN. KBC Group NV acquired a new position in Enliven Therapeutics in the first quarter valued at approximately $38,000. State of Wyoming purchased a new stake in Enliven Therapeutics in the 2nd quarter worth approximately $96,000. FNY Investment Advisers LLC acquired a new stake in shares of Enliven Therapeutics during the 2nd quarter worth approximately $126,000. Arizona State Retirement System grew its stake in shares of Enliven Therapeutics by 45.1% during the 2nd quarter. Arizona State Retirement System now owns 13,007 shares of the company’s stock worth $660,000 after purchasing an additional 4,042 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Enliven Therapeutics by 21.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 23,441 shares of the company’s stock valued at $919,000 after purchasing an additional 4,105 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.